ascopubs.org

IDOV-Safe: An intravenously deliverable oncolytic vaccinia virus for solid tumors refractory to standard of care—preliminary results from the pMMR/MSS CRC cohort.

Short-course radiotherapy followed by CAPOX combined with tislelizumab and bevacizumab or cetuximab for treatment-naive unresectable metastatic rectal cancer (UNION mRC). This is an ASCO Meeting ...
MarketWatch

ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV(TM) ...
The National Law Review

ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the ...
The National Law Review

ViroMissile Appoints Michael G. Wood as Chief Business Officer

SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the ...
Business Insider

ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the initiation ...
Business Insider

ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the expansion ...